A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients

Table 3 Dropout reason in BC and HNC patients

Reason for withdrawal	BC		HNC
Reason for withdrawal	*SOC (N = 8)*	*Xonrid® + SOC (N = 3)*	*SOC (N = 12)*	*Xonrid® + SOC (N = 6)*
*Grade > = 3 skin toxicity*	4 (50.0%)	1 (33.3%)	5 (41.7%)	6 (100.0%)
*Adverse event*	1 (12.5%)	1 (33.3%)	1 (8.3%)
*Lost to follow-up*	1 (12.5%)	1 (33.3%)	3 (25.0%)
*Consent withdrawal*	1 (12.5%)		3 (25.0%)
*Lack of compliance to study treatment or assessment*	1 (12.5%)

ISSN: 1748-717X